Decades of research on neuroblastoma have uncovered a multitude of factors that contribute to tumor progression and correlate with overall outcome, including patient age; disease stage; histological classification; molecular markers; genetic abnormalities, including MYCN amplification and mutations in genes such as ALK and ATRX; recurrent driver mutations, which are uncommon; and specific alterations associated with neuroblastoma metastasis, which are not fully understood and warrant further investigation. This evidence concerns the gene ATRX and neuroblastoma.